Semax and Stroke Recovery Research: Neuroprotection, BDNF and Clinical Applications (UK 2026)

Semax is a synthetic heptapeptide derived from the ACTH4-7 sequence — Met-Glu-His-Phe-Pro-Gly-Pro — developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Unlike most nootropic research peptides, Semax has an established clinical history in Russia: it has been registered as a pharmaceutical drug (Semaks) for stroke rehabilitation and cognitive impairment since the early 2000s. This clinical background provides an unusually rich evidence base for a research peptide, spanning human studies in stroke patients, traumatic brain injury, and cognitive decline in elderly populations. This guide focuses specifically on the stroke recovery and neuroprotection research that underpins Semax’s most clinically significant application.

Stroke Biology: Why Neuroprotection Research Matters

Ischaemic stroke — caused by arterial occlusion cutting off blood supply to brain tissue — accounts for approximately 87% of all strokes. The cellular biology of ischaemic injury proceeds in two phases with distinct therapeutic implications:

The ischaemic core is the region of brain tissue with most severely reduced perfusion, where neurons die within minutes due to ATP depletion and failure of ion pumps. This tissue is generally considered irreversibly damaged within the timeframe achievable with current interventions.

The penumbra is the surrounding zone of reduced but not absent perfusion — neurons here are electrically silent but structurally intact, potentially salvageable if perfusion is restored or cell death is prevented by neuroprotective interventions. The therapeutic window for penumbral salvage is approximately 4–6 hours from stroke onset (though reperfusion via thrombolytics or mechanical thrombectomy can extend this).

Beyond the acute phase, neuroplasticity and recovery occur over weeks to months as surviving neurons form new synaptic connections, and surviving oligodendrocytes remyelinate damaged axons. Interventions that enhance neuroplasticity during this subacute and chronic phase can meaningfully improve functional outcomes even when applied after the acute window has closed — and it is in this recovery phase that Semax’s research is most compelling.

Semax Mechanisms Relevant to Stroke Recovery

Semax’s neuroprotective and neuroregenerative effects in stroke research are attributable to several converging mechanisms:

BDNF upregulation: Brain-Derived Neurotrophic Factor (BDNF) is the most potent endogenous promoter of neuronal survival, synaptic plasticity, and neurogenesis. BDNF binds TrkB receptors on neurons, activating PI3K/Akt survival signalling and MAPK/ERK plasticity signalling — the cellular basis of long-term potentiation and memory consolidation. In ischaemic tissue, BDNF is critically needed for surviving penumbral neurons to maintain connectivity and eventually form compensatory circuits. Semax reliably elevates BDNF expression in rodent brain tissue — a finding reproduced across multiple laboratories and in both normal and ischaemic tissue. The magnitude of BDNF upregulation in ischaemia models is substantially larger than in normal tissue, suggesting a stress-responsive amplification mechanism.

NGF upregulation: Nerve Growth Factor supports the survival of cholinergic basal forebrain neurons — the source of cholinergic innervation of the cortex and hippocampus, critical for attention and memory. Cholinergic dysfunction contributes to post-stroke cognitive impairment. Semax’s NGF upregulation may preserve this system under ischaemic stress.

VEGF upregulation: Vascular Endothelial Growth Factor drives angiogenesis — the formation of new capillaries to restore blood supply to ischaemic tissue. Post-stroke angiogenesis in the perilesional zone is one of the mechanisms of natural recovery. Semax’s promotion of VEGF-driven angiogenesis may accelerate this vascular restoration process.

Anti-excitotoxicity: Glutamate excitotoxicity — excessive activation of NMDA receptors by glutamate released from depolarised ischaemic neurons — is a primary mechanism of ischaemic cell death in the penumbra. Semax demonstrates anti-excitotoxic properties in multiple models, reducing NMDA receptor-mediated calcium influx and the downstream activation of calcium-dependent destructive enzymes (calpain, caspases, phospholipases).

Inflammatory modulation: Post-stroke neuroinflammation — mediated by microglial activation, neutrophil infiltration, and cytokine production — exacerbates secondary injury in the days following ischaemic stroke. Semax modulates microglial activation and reduces pro-inflammatory cytokine (TNF-α, IL-1β) production in ischaemia models, potentially limiting this secondary inflammatory damage.

Animal Model Evidence

Semax has been studied in multiple established rodent stroke models:

In the middle cerebral artery occlusion (MCAO) model — the most widely used ischaemic stroke model — Semax administration both before and after occlusion reduces infarct volume (the size of the resulting brain lesion), improves neurological deficit scores, and accelerates functional recovery. The post-occlusion studies are particularly relevant because they model treatment rather than prophylaxis.

In models of global cerebral ischaemia (bilateral carotid occlusion), Semax preserves hippocampal neuronal density — critically important given the hippocampus’s key role in memory consolidation and its extreme vulnerability to ischaemic injury.

The dose-response and timing studies in rodent models suggest an optimal treatment window in the early post-ischaemic period — consistent with the clinical use in Russia, where Semax is administered within the first hours to days of stroke onset.

Russian Clinical Evidence

Semax’s registered clinical use in Russia provides human data that most research peptides lack:

Clinical studies in acute ischaemic stroke patients have demonstrated that intranasal Semax (300–600 mcg twice daily) administered within 6 hours of stroke onset produces statistically significant improvements in neurological deficit scores (assessed by the NIH Stroke Scale and related tools) at 1 week and 1 month compared to standard care alone. Functional outcomes at 3 months also showed improvement.

Studies in the subacute and rehabilitation phase (2 weeks to 3 months post-stroke) similarly show cognitive benefits — particularly in attention and memory domains that are commonly impaired post-stroke. Semax appears effective in this phase even when acute neuroprotection is no longer relevant — consistent with its mechanism of promoting neuroplasticity through BDNF and supporting the synaptic remodelling that underlies functional recovery.

Semax has also been studied in ischaemic optic neuropathy — a related condition involving ischaemic injury to the optic nerve — where it has demonstrated improvements in visual field and acuity parameters in some clinical cohorts.

Comparison with Selank in the Russian Neurological Context

Semax and Selank are often grouped together as Russian nootropic peptides, but their research profiles differ substantially in clinical orientation. Selank’s primary documented effects are anxiolytic and stress-modulating — most relevant for anxiety disorders and psychological stress. Semax’s research profile centres on neurotrophin upregulation and neuroprotection — most relevant for acute and subacute neurological injury and cognitive rehabilitation.

In practice, the two compounds may be complementary in certain research designs: Selank’s anxiolytic and cortisol-modulating effects could reduce the psychological stress response that accompanies neurological injury, while Semax’s neurotrophic effects drive tissue-level recovery. Combined research protocols examining both compounds in stroke recovery contexts would be scientifically well-motivated.

Traumatic Brain Injury Research

Beyond ischaemic stroke, Semax has been studied in traumatic brain injury (TBI) models. The secondary injury mechanisms in TBI — excitotoxicity, neuroinflammation, axonal degeneration, and disrupted neurotrophic support — overlap substantially with ischaemic stroke pathophysiology, making Semax’s mechanisms directly relevant. Animal TBI studies show Semax reducing lesion size, preserving cognitive function, and accelerating neurological recovery. Human TBI studies in Russian clinical literature report similar findings — reduced neurological deficits and improved cognitive outcomes in TBI patients treated with Semax.

Administration and Research Protocols

Semax is most studied via intranasal administration in both animal models and human trials. Intranasal delivery is particularly well-suited to CNS-targeted peptides: the olfactory epithelium provides a direct anatomical pathway to the olfactory bulb and adjacent limbic/cortical structures, bypassing the blood-brain barrier. This route avoids the proteolytic degradation that limits systemic bioavailability of peptides and concentrates drug delivery in the CNS compartment where it is needed.

Russian clinical protocols use intranasal drops (not spray) of Semax at concentrations of 0.1% (300 mcg per dose) to 1% (3,000 mcg per dose). The higher dose range is used in acute stroke; lower doses in subacute rehabilitation and cognitive enhancement contexts.

Summary

Semax occupies a unique position in the research peptide landscape: a compound with genuine clinical registration and human trial evidence for stroke rehabilitation, grounded in a mechanistically coherent model of neurotrophic factor upregulation and neuroprotection. For UK researchers working in neurology, stroke biology, traumatic brain injury, neuroplasticity, or cognitive rehabilitation, Semax offers a scientifically validated and mechanistically rich tool with a clinical evidence base rare in the research peptide space.